Chimeric Therapeutics has CLTX CAR T abstract accepted for prestigious annual meeting of American Society of Clinical Oncology
CHM has exclusive global rights to IP covering the Chlorotoxin CAR T which is in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumours such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer.
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Chimeric Therapeutics Ltd (ASX:CHM) has had the first CLTX CAR T abstract accepted for presentation at the prestigious annual meeting of the American Society of Clinical Oncology (ASCO), which is being virtually held from June 4-8.